{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:federal-register-2026-15285:v1","objectPathId":"federal-register-2026-15285-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/federal-register-2026-15285/","json":"https://peptidescanner.com/evidence/v1/objects/federal-register-2026-15285-v1.json","markdown":"https://peptidescanner.com/evidence/v1/objects/federal-register-2026-15285-v1.md"},"story":{"slug":"federal-register-2026-15285","version":1,"domain":"Regulatory","dateInSource":"2026-07-29","sourceCheckedAt":"2026-08-21","publishedAt":"2026-08-21","peptideSlugs":["glucagon","liraglutide","semaglutide","teriparatide","tirzepatide","vosoritide"],"peptides":[{"slug":"glucagon","url":"https://peptidescanner.com/peptides/glucagon/"},{"slug":"liraglutide","url":"https://peptidescanner.com/peptides/liraglutide/"},{"slug":"semaglutide","url":"https://peptidescanner.com/peptides/semaglutide/"},{"slug":"teriparatide","url":"https://peptidescanner.com/peptides/teriparatide/"},{"slug":"tirzepatide","url":"https://peptidescanner.com/peptides/tirzepatide/"},{"slug":"vosoritide","url":"https://peptidescanner.com/peptides/vosoritide/"}]},"claims":[{"id":"headline","text":"Federal Register notice 2026-15285","sourceIds":["federal-register-2026-15285-4fd72c0c3671"]},{"id":"summary","text":"The Federal Register published notice 2026-15285, attributed to FDA and its parent HHS department, on 2026-07-29. Its official title is “Product-Specific Guidances; Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide, Semaglutide, Teriparatide, Tirzepatide and Vosoritide.","sourceIds":["federal-register-2026-15285-4fd72c0c3671"]},{"id":"paragraph-1","text":"The Federal Register published notice 2026-15285, attributed to FDA and its parent HHS department, on 2026-07-29. Its official title is “Product-Specific Guidances; Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide, Semaglutide, Teriparatide, Tirzepatide and Vosoritide.","sourceIds":["federal-register-2026-15285-4fd72c0c3671"]},{"id":"paragraph-2","text":"This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use.","sourceIds":["federal-register-2026-15285-4fd72c0c3671"]}],"sources":[{"id":"federal-register-2026-15285-4fd72c0c3671","name":"Federal Register via GovInfo","sourceClass":"A","title":"Federal Register notice 2026-15285 · published 2026-07-29 · Product-Specific Guidances; Revised Draft Guidances for Industry; Availability","url":"https://www.govinfo.gov/content/pkg/FR-2026-07-29/pdf/2026-15285.pdf"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"31dbb2e24b7a77ab4b7c4d5ae0ae8f4ab5969890ad32c5e5236947d5c35c7714","tierARecordSha256":"4fd72c0c367194ba2b572c357337ac1529f699b1a1409ab85e91f51f0275aa68"},"integrity":{"algorithm":"sha256","contentSha256":"a349f767795fdf496c24789d1189838840368f7c9693be834f62e337f161a2c1"}}